← Back to catalogue
Published

etofibrate

vr.tr.etofibrate · thing-q4116990

Enable an agent to recognise etofibrate, assess the identity and condition of a particular sample, and determine whether evidence supports its proposed handling or use.

Thing Registry Physical world and living systems PHY.MAT

Bundle → Layer → Finding → Questions Filled

6 bundles · 11 layers · 16 findings · 26 questions

Etofibrate identity Establish the parent structure and the boundaries of the registered substance.

Covalent structure

Recognise the linked clofibric-acid and nicotinic-acid ester structure.

Linked diester identity

Etofibrate has a two-carbon bridge between its two ester groups; recognition requires the complete connectivity. [PubChem](https://pubchem.ncbi.nlm.nih.gov/compound/Etofibrate)

  1. Does the candidate structure contain both acid-derived groups joined through the ethylene glycol diester linkage? definition
  2. What structure-sensitive evidence distinguishes this sample from clofibrate or an unlinked mixture? measurement

Registry and form boundary

Resolve names and identifiers without merging chemically distinct forms.

Parent record resolution

Parent etofibrate is associated with EC 250-743-1 and UNII 23TF67G79M alongside its CAS and PubChem identifiers. [PubChem](https://pubchem.ncbi.nlm.nih.gov/compound/Etofibrate)

  1. Which authoritative record supports each identifier and its mapping to vr.tr.etofibrate? provenance
  2. Does the supplied material represent the parent, a salt, a solution, or a formulated product requiring a separate linked record? boundary
Etofibrate lot quality Assess how much intact etofibrate a lot contains and what accompanies it.

Identity and assay

Connect analytical identity and quantitative content to a specific lot.

Intact parent content

Record identity confirmation separately from assay and chromatographic purity, with standards and reporting bases.

  1. Which analytical methods and reference standard establish intact etofibrate identity in this lot? provenance
  2. What is the etofibrate assay, its uncertainty, and its as-is or corrected reporting basis? measurement

Related substances

Account for compounds and residues that accompany the parent substance.

Impurity discrimination

Investigate constituent acids, possible partial hydrolysis products, process residues, and unknown peaks without assuming they occur in every lot.

  1. Does the analytical method resolve etofibrate from clofibric acid, nicotinic acid, and relevant partially cleaved species? measurement
  2. Which impurity, water, and residual-solvent limits apply to the proposed grade, and does this lot meet them? action
Physical state and preparation Describe observed bulk material and the conditions under which usable solutions can be prepared.

Bulk form and thermal properties

Record phase, solid-state evidence, and measured thermal behaviour.

Condition-qualified physical properties

Attach sample form and method to thermal measurements; leave unverified constants unresolved.

  1. What physical phase and, where established, crystalline or amorphous form does this etofibrate sample exhibit? measurement
  2. Which melting or decomposition observations are experimentally supported, and is any reported boiling point measured or estimated? provenance

Solution preparation

Assess dissolution and persistence of intact parent under proposed preparation conditions.

Solubility with integrity

A useful solubility result must distinguish dissolved etofibrate from suspended material or chemically transformed material.

  1. What concentration of intact etofibrate is achieved in the stated solvent at the stated temperature, pH, and equilibration time? measurement
  2. What preparation and holding conditions maintain the required dissolved concentration and parent content? action
Ester integrity and transformation Track changes to the intact diester and distinguish chemical stability from biological conversion.

Storage and exposure stability

Evaluate parent retention under documented environmental and solution conditions.

Condition-dependent parent loss

Treat sensitivity to moisture, pH, heat, or light as an empirical question and record identified products alongside parent loss.

  1. How does intact etofibrate content change with time under the actual storage or solution conditions? measurement
  2. Which observations justify the storage condition, retest interval, or prepared-solution holding time? action

Transformation product attribution

Relate parent etofibrate to identified cleavage products without transferring their properties automatically.

Parent and product separation

Record the evidence for cleavage pathways and distinguish observations about intact etofibrate from observations about products or mixtures.

  1. Which products and intermediates are directly identified after chemical or biological exposure, and under what conditions? provenance
  2. Does a reported effect concern intact etofibrate, a measured transformation product, or an unresolved combination? boundary
Handling and use evidence Connect the actual etofibrate material to documented hazards and requirements for its intended activity.

Hazards and exposure controls

Establish applicable hazard evidence for the parent material and any preparation containing it.

Applicable hazard record

Record classification, supporting evidence, and exposure-control requirements with jurisdiction, date, and material form.

  1. What current GHS classification and exposure-limit evidence applies specifically to etofibrate in the relevant jurisdiction? provenance
  2. What handling, containment, spill, and disposal measures follow from the actual powder or solution documentation? action

Grade and use eligibility

Determine whether the documented lot supports the intended activity.

Evidence-based use decision

Keep research-material status, pharmaceutical quality, and finished-product authorisation as distinct determinations.

  1. Which lot documents and applicable requirements support the proposed research or manufacturing use? provenance
  2. What missing identity, quality, stability, or regulatory evidence requires the agent to hold this lot from that use? action
Evidence and external alignment What the world already says about this thing, gathered so the model can be checked against it.

Reported evidence

Findings from the breadth pass, kept separate from the structural claims.

Check these first

Recalled without web access and unsourced; every item is a lead to verify.

  1. Which of these check these first hold for the sense of etofibrate this model covers, and on what evidence? provenance

Identifiers and schemes

Recalled without web access and unsourced; every item is a lead to verify.

  1. Which of these identifiers and schemes hold for the sense of etofibrate this model covers, and on what evidence? provenance

Real-world use

Recalled without web access and unsourced; every item is a lead to verify.

  1. Which of these real-world use hold for the sense of etofibrate this model covers, and on what evidence? provenance

Typical measurements

Recalled without web access and unsourced; every item is a lead to verify.

  1. Which of these typical measurements hold for the sense of etofibrate this model covers, and on what evidence? provenance

Failure modes and hazards

Recalled without web access and unsourced; every item is a lead to verify.

  1. Which of these failure modes and hazards hold for the sense of etofibrate this model covers, and on what evidence? provenance

Neighbouring kinds and how to tell them apart

Recalled without web access and unsourced; every item is a lead to verify.

  1. Which of these neighbouring kinds and how to tell them apart hold for the sense of etofibrate this model covers, and on what evidence? provenance

Classifiers Filled

Family
Thing Registry
Category
Physical world and living systems
Entry kind
thing
Plane
PHY
Domain
PHY.MAT

What it is Filled

Etofibrate is a synthetic lipid-lowering compound in which clofibric acid and nicotinic acid are joined through an ethylene glycol diester linkage.

In scope

  • Parent etofibrate identity and differentiation from related fibrates, salts, and mixtures
  • Lot-specific assay, impurities, residual solvents, water content, and grade
  • Physical form, measured properties, and their experimental conditions
  • Ester integrity, degradation, and relationships to transformation products
  • Substance-specific handling evidence and jurisdiction-dependent use constraints

Out of scope

  • Finished medicines, formulations, packaging, and product authorisations
  • Patient diagnosis, prescribing, dosing, and treatment monitoring
  • Manufacturing routes and production equipment
  • Independent models of clofibrate, clofibric acid, nicotinic acid, or ethylene glycol
  • Separate substance identities for salts or derivatives unless registry policy explicitly includes them

Why it exists Filled

Enable an agent to recognise etofibrate, assess the identity and condition of a particular sample, and determine whether evidence supports its proposed handling or use.

Distinguishing features Filled

  • Match the parent structure to C18H18ClNO5 and InChIKey XXRVYAFBUDSLJX-UHFFFAOYSA-N; formula alone cannot establish identity. [PubChem](https://pubchem.ncbi.nlm.nih.gov/compound/Etofibrate)
  • Confirm an ethylene glycol bridge esterified with clofibric acid and nicotinic acid: this distinguishes etofibrate from clofibrate's ethyl ester and from an unlinked mixture. [NLM MeSH](https://meshb.nlm.nih.gov/record/ui?ui=C009746)
  • Resolve identifiers to parent etofibrate, CAS 31637-97-5 and PubChem CID 65777; do not silently substitute the separately listed hydrochloride, CAS 56775-91-8. [PubChem](https://pubchem.ncbi.nlm.nih.gov/compound/Etofibrate)
  • Require analytical evidence for intact etofibrate rather than treating detection of a constituent acid or a related fibrate as confirmation of the parent substance.

What robots and AI may and may not do Filled

Must not

  • Recommend, dose or supply it to a person without a prescriber's decision.
  • Advise combining it with other lipid drugs without medical supervision.
  • Claim cardiovascular benefits that trials have not shown.

Only with a human decision

  • Any decision to start, stop or change lipid-lowering treatment.

May

  • Describe etofibrate's composition and lipid-lowering purpose from authoritative sources.
  • Note that availability differs between countries.

Moral aspects Filled

  • Patients need honest information about the evidence behind older lipid drugs.

Who is affected

  • Patients
  • Prescribers

Owners Filled

Steward

The marketing authorisation holder where it is licensed; the prescriber answers for each use.

Master systems

  • National medicines registers

Links to other meta-models Filled

parent

  • Q11173 - registry parent class

What else AI and robots need to interact with it Filled

Identity and identifiers required Filled

  • Vercy registry: vr.tr.etofibrate
  • Wikidata: Q4116990 (https://www.wikidata.org/wiki/Q4116990)

Direct properties required Filled

  • Parent molecular identity: C18H18ClNO5; structure-resolved identifier and reference record
  • Substance form: Parent; salt with counterion and stoichiometry; other derivative; unresolved
  • Assay and reporting basis: % mass fraction or chromatographic area %, explicitly distinguished; as-is or corrected basis
  • Impurity profile: Identified and unidentified impurities in % or mg/kg; method and quantification limits
  • Water and residual solvents: Water in % mass fraction; individual solvents in mg/kg
  • Physical form and thermal behaviour: Observed phase and solid form at stated temperature; thermal transitions in °C with method
  • Solubility: mg/mL or mol/L with solvent, temperature, pH where applicable, and equilibration time
  • Parent integrity over time: % parent remaining and product concentrations at specified times and conditions
  • Hazard evidence status: Verified classification; conflicting evidence; insufficient data; source jurisdiction and revision date
  • Permitted-use relationship: Material lot linked to documented grade, intended activity, jurisdiction, and applicable requirements

Recognition required Filled

  • Identity cannot be settled by sight; capsules or tablets must be confirmed by label and pharmacy records.

Capabilities and actions required Filled

  • Reconcile a supplier label or registry record with the parent etofibrate structure and flag form mismatches.
  • Assess a lot against documented identity, assay, impurity, and grade requirements.
  • Evaluate a proposed solvent and preparation condition using measured solubility and parent-integrity evidence.
  • Detect and track conversion of intact etofibrate during storage or experimental exposure.
  • Select handling and disposal instructions from applicable substance and mixture documentation.
  • Hold material from a proposed use when identity, condition, or use requirements remain unresolved.

Hazards and failure modes required Filled

  • Fibrate and nicotinic acid components can cause muscle, liver and flushing side effects.
  • Interactions with other drugs, such as anticoagulants or statins, need medical review.

Standards and interfaces required Filled

  • The World Health Organization Collaborating Centre for Drug Statistics Methodology classifies etofibrate under ATC code C10AB09 within the fibrates.

Context of use required Filled

  • Etofibrate is encountered in pharmaceutical literature and analytical research concerning compounds used to lower blood lipid levels.
  • Its identity and composition matter when interpreting historical medicines, reference materials and laboratory samples.

Sources Filled

  1. Wikidata item Q4116990: etofibrate - identity and sense of the item
  2. Wikipedia: Etofibrate - general description of the item

Open questions

  • Which primary measurements establish etofibrate's melting behaviour, solid forms, and solvent-specific solubility, and is a meaningful boiling point available before decomposition?
  • What validated analytical methods distinguish intact etofibrate from constituent acids, partial hydrolysis intermediates, and relevant manufacturing impurities?
  • What hydrolysis pathways, rates, and storage limits are supported under dry storage, aqueous preparation, and biological exposure conditions?
  • What current substance-specific GHS classifications, occupational exposure limits, and disposal requirements apply in the intended jurisdiction?
  • Which authoritative quality standards and current jurisdiction-specific records establish acceptable grades and permitted uses of etofibrate?

Machine files

Provenance

thing registry research (pass 2) · unreviewed

Built from: models/things/publications/thing-q4116990/spec.json